This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted